Numerous recalls have been initiated in 2025 due to the potential for damaged products, foodborne illness, contamination and ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Q2 2025 Earnings Call Transcript August 5, 2025 Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported ...

Swiss pharma giant Novartis AGNVS reported better-than-expected results for the second quarter of 2025 and upped annual guidance for core operating income. Core earnings (excluding one-time charges) ...

Novo Nordisk NVO is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks ...

BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions.

Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the approval by the US Food and Drug Administration of a label update for ...

The FDA has expanded the label of Bayer’s kidney disease drug Kerendia to include treatment of patients with two types of heart failure.

An FDA expert panel has reignited a decades-old debate over hormone therapy treatment for menopause, as advocates argue over black box warnings and and a controversial 20th-century study.

Bayer AG BAYRY announced that the FDA has approved a label expansion of kidney disease drug Kerendia (finerenone). The regulatory body approved finerenone for the treatment of adult patients with ...

FDA Approves Kisunla Label Update: New titration dosing schedule for Kisunla (donanemab-azbt) reduces risk of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) in early symptomatic ...

Consumer Reports and Unleaded Kids evaluated baby food brands for compliance with California’s AB899 requiring heavy metal ...